ImmunityBio, Inc. IBRX Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s other commercial liabilities?
- ImmunityBio, Inc. (IBRX) reported other commercial liabilities of $48.2M in Q1 2026.
- How has ImmunityBio, Inc.'s other commercial liabilities changed year-over-year?
- ImmunityBio, Inc.'s other commercial liabilities increased by 72.8% year-over-year, from $27.89M to $48.2M.
- What is the long-term trend for ImmunityBio, Inc.'s other commercial liabilities?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s other commercial liabilities has grown at a 5.0% compound annual growth rate (CAGR), from $36.77M to $46.84M.